Molecular, Cellular, and Tissue Characterization Unit
分子、细胞和组织表征单元
基本信息
- 批准号:10900845
- 负责人:
- 金额:$ 25.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-04-04 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAgeAntibodiesAntigensAtlasesBiological AssayBiopsyBone MarrowBreslow ThicknessCell LineCellsCollaborationsCollectionCompetenceCore FacilityCutaneousDNADNA DamageDNA Sequence AlterationDNA sequencingDataData CollectionDimensionsDisadvantagedDisease ProgressionElementsEnsureEvaluationEventFee-for-Service PlansFixativesFlow CytometryGene ExpressionGene FrequencyGene MutationGenesGenetic TranscriptionGenotypeHealth Services ResearchHematologyHeterogeneityHybridsImageImage CytometryImmuneKnowledgeLabelLaboratoriesLasersLearningLesionLettersLinkLongitudinal cohortMaintenanceMapsMeasurementMeasuresMetadataMethodsMicroscopeMitochondriaModalityMolecularMorphologyMultiplexed Ion Beam ImagingMutationNeoplasmsOpticsPathologistPatientsPhasePlayPoliciesProceduresProspective cohortProteinsProtocols documentationQuality ControlRNA SequencesReagentReproducibilityResearch PersonnelResolutionRoleSamplingScanningSeriesSkinSpecimenStainsStandardizationSubcellular structureSystemT cell clonalityT cell receptor repertoire sequencingTechniquesTechnologyTechnology AssessmentTestingThree-Dimensional ImagingTimeTissue SampleTissuesTrainingWorkcell transformationdata pipelineexperiencefluorophoregenetic varianthigh dimensionalityhigh resolution imagingimprovedindividual patientinformation processinginnovationinstrumentlaser capture microdissectionmRNA Expressionmelanomamembermetadata standardsmultidimensional datamultiplexed imagingmutational statuspremalignantprospectivequality assurancereconstructionsample fixationsingle-cell RNA sequencingtranscriptome sequencingtumor progressionultra high resolution
项目摘要
CHARACTERIZATION UNIT - SUMMARY ABSTRACT
The Characterization Unit will oversee collection of all image and omic data needed for construction
of multi-parametric Atlases of MP lesions and CHIP specimens. Following a technology
assessment/consolidation phase in year 1 most data collection will take place in the LSP and established
core facilities as a means to ensure reproducibility. The Characterization Unit will work with the Analysis
Unit to establish a robust information processing system that maintains the reliability of data and metadata
collection and storage for Atlas specimens and QC/QA samples. Metadata will include the elements
needed to comply with FAIR standards. Dissociative technologies such as single cell-RNA sequencing,
DNA sequencing, and FACS/CyTOF will provide the highest dimensional data for Atlas construction but
only on cells outside of their tissue context. Highly multiplexed imaging of FFPE biopsies will be used to
collect spatially resolved data on cell states and morphology as well as expression of selected genes and
genotypes (using padlock-rolling circle amplification probes). For the MP Atlas, laser capture of FFPE
specimens will be followed by assessment of mutational status by WES, T cell clonality by TCR-seg and
RNA expression by RNA-Seq. The Analysis unit will use multi-view learning and related methods to
integrate the resulting spatial and omic data and to deconvolute bulk RNA sequence when scRNAseq is not
possible (i.e. when analyzing FFPE MPs). Standard operating protocols developed in the Center will be
evaluated and disseminated to other HTAN members.
Aim 1 will characterize changes in gene expression, acquisition of mutations and cell-cell
heterogeneity by sequencing, flow cytometry and CyTOF. Padlock-based FISH will be used to provide
single-cell resolution of mRNA expression and mutational status. Aim 2 will collect high dimensional high
resolution of images from FFPE specimens at using two complementary techniques: t-CyCIF and DEI.
Antibodies will be rigorously tested and QA/QC data linked to Atlas images. A sub-set of CHIP and MP
samples will be analyzed in 3D using serial sections. Aim 3 will collect time-series data from serial biopsies
of CHIP patients in a longitudinal cohort and deep UMI sequencing and flow cytometry will be used to
assay variant allele frequency and clonal progression. Aim 4 will implement quality assurance policies
inspired by experience of quality assurance officer and pathologist Sandro Santagata in a CLIA setting.
This will involve SOPs, routine retesting, competency training and statistical quality control. Aim 5 will
evaluate new or improved technologies developed by PATCH Center members, other Centers in the HTAN
network, collaborating investigators and companies (see letters of support). This includes direct comparison
of t-CyCIF and DEI with Multiplexed Ion Beam Imaging (MIBI) now available at HMS and Scanning Mass
Cytometry Imaging implemented in the Bodenmiller Lab in Zurich.
表征单元-摘要
表征股将监督收集施工所需的所有图像和组学数据
MP病变和CHIP标本的多参数分析。在一项技术
第一年的评估/整合阶段,大部分数据收集将在LSP中进行,
核心设施作为确保可重复性的手段。特性描述股将与分析小组合作,
该股建立一个强有力的信息处理系统,以保持数据和元数据的可靠性
采集和储存Atlas标本和QC/QA样本。元数据将包括
必须符合FAIR标准。解离技术如单细胞RNA测序,
DNA测序和FACS/CyTOF将为Atlas构建提供最高维度的数据,
只在组织环境之外的细胞上。FFPE活检的高度多重成像将用于
收集关于细胞状态和形态以及所选基因表达的空间分辨数据,
基因型(使用锁式滚环扩增探针)。对于MP Atlas,FFPE的激光捕获
随后将通过WES评估突变状态,通过TCR-seg评估T细胞克隆性,
通过RNA-Seq.分析单元将使用多视图学习和相关方法,
整合得到的空间和组学数据,并在scRNAseq不
可能(即分析FFPE MP时)。中心制定的标准操作规程将
评估并分发给其他HTAN成员。
目的1将描述基因表达的变化,突变的获得和细胞-细胞
通过测序、流式细胞术和CyTOF分析异质性。基于挂锁的FISH将用于提供
mRNA表达和突变状态的单细胞分辨率。目标2将收集高维高
使用两种互补技术:t-CyCIF和DEI,从FFPE标本中获得的图像分辨率。
抗体将经过严格测试,QA/QC数据将与Atlas图像相关联。CHIP和MP的子集
将使用连续切片在3D中分析样品。AIM 3将从连续活检中收集时间序列数据
的CHIP患者,深度UMI测序和流式细胞术将用于
测定变体等位基因频率和克隆进展。目标4将实施质量保证政策
灵感来自于质量保证官和病理学家Sandro Scarlata在CLIA环境中的经验。
这将涉及SOP、常规复检、能力培训和统计质量控制。目标5将
评估PATCH中心成员、HTAN其他中心开发的新技术或改进技术
网络,合作调查人员和公司(见支持信)。这包括直接比较
t-CyCIF和DEI与多路离子束成像(MIBI)现已在HMS和扫描质谱
在苏黎世的Bodenmiller实验室实施细胞计数成像。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sandro Santagata其他文献
Sandro Santagata的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sandro Santagata', 18)}}的其他基金
Mechanisms promoting copper dependent cell death in cancer
促进癌症中铜依赖性细胞死亡的机制
- 批准号:
10637427 - 财政年份:2023
- 资助金额:
$ 25.44万 - 项目类别:
Heat Shock Directed Drug Discovery For The Treatment Of Gliomas
热休克定向治疗神经胶质瘤的药物发现
- 批准号:
8113310 - 财政年份:2008
- 资助金额:
$ 25.44万 - 项目类别:
Heat Shock Directed Drug Discovery For The Treatment Of Gliomas
热休克定向治疗神经胶质瘤的药物发现
- 批准号:
7937847 - 财政年份:2008
- 资助金额:
$ 25.44万 - 项目类别:
Heat Shock Directed Drug Discovery For The Treatment Of Gliomas
热休克定向治疗神经胶质瘤的药物发现
- 批准号:
7572020 - 财政年份:2008
- 资助金额:
$ 25.44万 - 项目类别:
Heat Shock Directed Drug Discovery For The Treatment Of Gliomas
热休克定向治疗神经胶质瘤的药物发现
- 批准号:
7683821 - 财政年份:2008
- 资助金额:
$ 25.44万 - 项目类别:
Heat Shock Directed Drug Discovery For The Treatment Of Gliomas
热休克定向治疗神经胶质瘤的药物发现
- 批准号:
8308011 - 财政年份:2008
- 资助金额:
$ 25.44万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 25.44万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 25.44万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 25.44万 - 项目类别:
Fellowship
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 25.44万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 25.44万 - 项目类别:
Continuing Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 25.44万 - 项目类别:
Standard Grant
The economics of (mis)information in the age of social media
社交媒体时代(错误)信息的经济学
- 批准号:
DP240103257 - 财政年份:2024
- 资助金额:
$ 25.44万 - 项目类别:
Discovery Projects
How age & sex impact the transcriptional control of mammalian muscle growth
你多大
- 批准号:
DP240100408 - 财政年份:2024
- 资助金额:
$ 25.44万 - 项目类别:
Discovery Projects
Supporting teachers and teaching in the age of Artificial Intelligence
支持人工智能时代的教师和教学
- 批准号:
DP240100111 - 财政年份:2024
- 资助金额:
$ 25.44万 - 项目类别:
Discovery Projects
Enhancing Wahkohtowin (Kinship beyond the immediate family) Community-based models of care to reach and support Indigenous and racialized women of reproductive age and pregnant women in Canada for the prevention of congenital syphilis
加强 Wahkohtowin(直系亲属以外的亲属关系)以社区为基础的护理模式,以接触和支持加拿大的土著和种族育龄妇女以及孕妇,预防先天梅毒
- 批准号:
502786 - 财政年份:2024
- 资助金额:
$ 25.44万 - 项目类别:
Directed Grant